Hemoptysis in Quadriplegia with Atrial Fibrillation Who Was Taking Edoxaban: a Case Report.
Hoyoung JeongBo Young HongJoon Sung KimJisoo ParkJi Yoon JungSeong-Hoon LimPublished in: Brain & NeuroRehabilitation (2021)
The direct-acting oral anticoagulants (DOACs) would be the standard treatment for the prevention of stroke and thromboembolism in nonvalvular atrial fibrillation patients. The adverse effects of greatest concern are bleeding especially major bleeding. We present a case of a patient with a history of nonvalvular atrial fibrillation and pacemaker, who developed severe anemia after massive hemoptysis while taking DOAC; however, he has continued taking DOAC. Through this case, we have summarized the current management of major bleeding associated with anticoagulation and discuss the optimal regimen for restarting of anticoagulation therapy.
Keyphrases
- atrial fibrillation
- direct oral anticoagulants
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- end stage renal disease
- chronic kidney disease
- venous thromboembolism
- heart failure
- percutaneous coronary intervention
- newly diagnosed
- ejection fraction
- case report
- peritoneal dialysis
- prognostic factors
- stem cells
- emergency department
- drug induced
- acute coronary syndrome
- mesenchymal stem cells
- blood brain barrier
- subarachnoid hemorrhage
- iron deficiency